{"url":"https://newsforagent.com/news/2026-11-20/quanta-qtx3034-endometrial-cancer-response","markdown_url":"https://newsforagent.com/news/2026-11-20/quanta-qtx3034-endometrial-cancer-response.md","title":"Quanta Therapeutics QTX3034 Shows 55% Response in Endometrial Cancer","headline":"Quanta Therapeutics Reports 55% Response Rate for QTX3034 in KRAS G12D Endometrial Cancer","description":"Quanta Therapeutics reported a 55% objective response rate for QTX3034 monotherapy in 11 patients with KRAS G12D-mutant endometrial cancer at the ENA Symposium 2026.","section":"Research & Clinical Trials","published_at":"2026-11-20T12:36:05+00:00","modified_at":"2026-11-20T12:36:05+00:00","author":"News Desk","key_takeaways":["QTX3034 monotherapy achieved a 55% objective response rate in 11 patients with KRAS G12D-mutant endometrial cancer, including one complete response.","The median duration of response was 9.7 months and the median time to response was 1.3 months.","Four of five patients with endometrioid histology, or 80%, achieved an objective response."],"companies":[{"name":"Quanta Therapeutics","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000mqg/quanta-therapeutics","website":"https://www.quantatx.com"}],"source":{"publisher":"GlobeNewswire","title":"Quanta Presents Class-Leading Monotherapy Data for QTX3034 in KRAS G12D-Mutant Advanced Endometrial Cancer at the EORTC-NCI-AACR Symposium","url":"https://www.globenewswire.com/news-release/2026/11/20/3407355/0/en/quanta-presents-class-leading-monotherapy-data-for-qtx3034-in-kras-g12d-mutant-advanced-endometrial-cancer-at-the-eortc-nci-aacr-symposium.html"},"other_sources":[],"tags":["Research & Clinical Trials","Quanta Therapeutics"],"body_markdown":"Quanta Therapeutics reported a 55% objective response rate for its oral KRAS inhibitor QTX3034 as a monotherapy in 11 patients with KRAS G12D-mutant endometrial cancer, including one complete response. The data were presented at the EORTC-NCI-AACR Symposium 2026, [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/20/3407355/0/en/quanta-presents-class-leading-monotherapy-data-for-qtx3034-in-kras-g12d-mutant-advanced-endometrial-cancer-at-the-eortc-nci-aacr-symposium.html) reported on November 20, 2026.\n\n## Quanta's QTX3034 Monotherapy Results\n\n[Quanta Therapeutics](https://akta.pro/company-profiles/0000mqg/quanta-therapeutics) is a privately held, clinical-stage biopharmaceutical company developing oral small-molecule inhibitors of KRAS G12D and G12V for RAS-driven cancers, including pancreatic, colorectal, lung and endometrial tumors. The 11 patients in the endometrial cancer cohort had received a median of four prior lines of therapy, and all had mismatch repair-proficient tumors and prior chemotherapy and immune checkpoint inhibitor therapy.\n\nResponses occurred rapidly, with a median time to response of 1.3 months, and were durable, with a median duration of response of 9.7 months. Four of five patients with endometrioid histology, or 80%, achieved an objective response. QTX3034 was generally well tolerated, with primarily low-grade adverse events and no treatment-related adverse events leading to discontinuation.\n\n\"These results provide encouraging evidence that direct KRAS inhibition can drive meaningful and durable tumor responses in patients with KRAS G12D-mutant endometrial cancer who have progressed following established therapies,\" said Judy S. Wang, M.D., of Florida Cancer Specialists/Sarah Cannon Research Institute and presenting author of the study.\n\n## Quanta's Funding and Pipeline\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Quanta has raised over $142 million since its founding in 2018, including a $50.7 million Series D in May 2023. The company has three KRAS inhibitor programs in clinical development: QTX3034, QTX3046 and QTX3544. KRAS mutations occur in approximately 25% of all human cancers.\n\n## Earlier QTX3034 Data at ESMO\n\nIn October 2026, Quanta presented positive clinical data for QTX3034 combined with cetuximab and/or chemotherapy in KRAS G12D-mutant colorectal cancer at ESMO 2026, showing a 25% overall response rate and 75% disease control with no new safety signals, GlobeNewswire reported. Earlier that month, the FDA granted Fast Track designation for the drug in KRAS G12D-mutant patients, according to Business & Financial.\n\n## What to Watch Next\n\nQuanta said the endometrial cancer data support further development of QTX3034 in this molecularly defined subset. The company has not announced a date for that next study.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}